Septerna, Inc. (SEPN)
NASDAQ: SEPN · Real-Time Price · USD
21.49
-0.45 (-2.05%)
Oct 30, 2025, 4:00 PM EDT - Market closed
Septerna Revenue
Septerna had revenue of $119.00K in the quarter ending June 30, 2025, a decrease of -67.84%. This brings the company's revenue in the last twelve months to $726.00K, down -13.37% year-over-year. In the year 2024, Septerna had annual revenue of $1.08M with 611.92% growth.
Revenue (ttm)
$726.00K
Revenue Growth
-13.37%
P/S Ratio
1,319.74
Revenue / Employee
$9,680
Employees
75
Market Cap
958.13M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 1.08M | 924.00K | 611.92% |
| Dec 31, 2023 | 151.00K | - | - |
| Dec 31, 2022 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionSEPN News
- 4 weeks ago - Septerna Appoints Veteran Biotechnology Leader Keith Gottesdiener, M.D., to its Board of Directors - GlobeNewsWire
- 2 months ago - Septerna to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 2 months ago - Septerna Announces Dosing of the First Participants in Phase 1 Clinical Trial of SEP-631, an Oral Small Molecule MRGPRX2 Negative Allosteric Modulator for the Treatment of Mast Cell-Driven Diseases - GlobeNewsWire
- 2 months ago - Septerna Highlights Business Progress and Reports Second Quarter 2025 Financial Results - GlobeNewsWire
- 4 months ago - Analyst Flags Septerna As Undervalued Biotech Play With Significant Upside - Benzinga
- 5 months ago - Septerna to Present at Jefferies Global Healthcare Conference - GlobeNewsWire
- 5 months ago - Septerna: Novo's Investment In Incretin Program Intrigues - One For The Watchlist - Seeking Alpha
- 5 months ago - Septerna: Deal With Novo Nordisk Is A Game Changer While It Still Trades Well Below Net Cash - Seeking Alpha